Island Pharmaceuticals (ASX:ILA) 1-Year Sharpe Ratio: 1.27 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ILA Island Pharmaceuticals Ltd ASX:ILA
30 GF Score
Price A$0.42
! 1 Warning Sign
View Full Analysis

What is Island Pharmaceuticals 1-Year Sharpe Ratio?

Island Pharmaceuticals ASX:ILA -1.19% 30 1-Year Sharpe Ratio is 1.27 as of Jul. 17, 2026. GuruFocus rates ASX:ILA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-17), Island Pharmaceuticals's 1-Year Sharpe Ratio is 1.27.

Island Pharmaceuticals  (ASX:ILA) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Island Pharmaceuticals 1-Year Sharpe Ratio Related Terms

ASX:ILA vs VRTX, REGN, ALNY: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, Island Pharmaceuticals's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Island Pharmaceuticals 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Island Pharmaceuticals's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Island Pharmaceuticals's 1-Year Sharpe Ratio falls into.


ASX:ILA
30GF Score
Island Pharmaceuticals Ltd ASX:ILA
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Island Pharmaceuticals 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 1.27 mean?
Island Pharmaceuticals (ASX:ILA) has a 1-Year Sharpe Ratio of 1.27 as of Jul. 17, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Island Pharmaceuticals and its competitors.
Is Island Pharmaceuticals' 1-Year Sharpe Ratio too high?
Island Pharmaceuticals' current 1-Year Sharpe Ratio is 1.27. Overall, Island Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' 1-Year Sharpe Ratio compare to VRTX and REGN?
Island Pharmaceuticals' 1-Year Sharpe Ratio of 1.27 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Island Pharmaceuticals and its competitors. Island Pharmaceuticals's current 1-Year Sharpe Ratio is 1.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current 1-Year Sharpe Ratio of 1.27. The current 1-Year Sharpe Ratio is 1.27. Island Pharmaceuticals' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current 1-Year Sharpe Ratio is 1.27 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Island Pharmaceuticals Business Description

Address c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
30GF Score

Get the complete analysis for ASX:ILA

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price